S-1/A: Cortigent Eyes $15 Million IPO to Advance Neurostimulation Technologies

Cortigent, a neurostimulation technology company, is seeking to raise $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Summary

• Cortigent, Inc., a company focused on developing neurostimulation systems, is planning an initial public offering (IPO) of 1,500,000 shares of common stock.
• The anticipated IPO price is $10.00 per share.
• The company aims to use the net proceeds, estimated at $12.92 million (or $14.99 million if underwriters fully exercise their option), primarily for research and development of its Orion visual prosthesis and stroke recovery system.
• A portion of the proceeds will also be used to repay amounts owed to its parent company, Vivani Medical, Inc.
• Cortigent's lead product candidates include the Orion Visual Cortical Prosthesis System (Orion) for artificial vision and a neurostimulation system for stroke recovery.
• The company has completed an early feasibility study for Orion and plans to commence a pivotal clinical trial by mid-2026, with a potential market launch in early 2029.
• For the stroke recovery system, Cortigent aims to begin an early feasibility study in mid-2026 and a pivotal trial in late 2027, targeting a market launch in late 2029.
• Cortigent has an extensive intellectual property portfolio with 207 issued U.S. patents and 20 issued European patents.
• The company is currently pre-revenue and expects to incur operating losses for the foreseeable future.
• Post-IPO, Vivani Medical, Inc. will beneficially own approximately 77% of Cortigent's voting power (or 74% if the underwriters exercise their option in full), making Cortigent a controlled company under Nasdaq rules.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While Cortigent is developing innovative technologies with significant market potential, it is a pre-revenue company with a history of losses and faces substantial risks in clinical development and regulatory approval. The company's reliance on additional funding and the control by its parent company also contribute to a neutral sentiment.

Positives

• Cortigent is developing innovative neurostimulation technologies with the potential to address significant unmet medical needs.
• The company has an existing intellectual property portfolio.
• The company is targeting large addressable markets with its Orion and stroke recovery systems.
• The company has completed an early feasibility study for Orion, showing positive efficacy data in some subjects.
• The company has received Breakthrough Device designation from the FDA for Orion, which could expedite the regulatory process.

Negatives

• Cortigent is a pre-revenue company with a history of operating losses and expects to continue incurring losses.
• The company's future success depends on the successful completion of clinical trials, regulatory approvals, and market acceptance of its products.
• Clinical development of medical devices is a lengthy and expensive process with an uncertain outcome.
• The company will be a controlled company post-IPO, which could limit the influence of other shareholders.
• The company will require substantial additional capital to support its clinical trials and growth plans.

Risks

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• The company's commercial and financial success depends on its future products being accepted in the market.
• Cortigent may face substantial competition in the future and may not be able to keep pace with rapid technological changes.
• The results of Cortigent's limited initial trials may not be predictive of future trial results.
• The company will require substantial additional capital to support its clinical trials and growth plans, and such capital may not be available on acceptable terms.
• The price of the company's common stock may be volatile, and the value of your investment could decline.
• The company is subject to stringent domestic and foreign medical device regulation, and any unfavorable regulatory action may materially and adversely affect its financial condition and business operations.

Future Outlook

Cortigent is targeting to commence a pivotal clinical trial for Orion by mid-2026, complete it by mid-2028, and launch Orion on the US market in early 2029. For the stroke recovery system, the company aims to commence an early feasibility study in mid-2026 and a pivotal trial in late 2027, targeting a market launch in late 2029. These timelines are subject to FDA discussions and financing availability.

Management Comments

• Management estimates that the Orion system has a total addressable U.S. market size that could potentially exceed $4 billion at the time of launch.
• Management estimates that the stroke recovery system could potentially benefit up to 195,000 U.S. stroke victims each year, creating a total addressable market estimated at approximately $6 billion by the time of system launch.

Industry Context

Cortigent operates in the competitive medical device industry, facing competition from companies developing visual prostheses and stroke rehabilitation devices. Competitors include Pixium Vision SA, Nano Retina Inc., Bionic Vision Technologies, MicroTransponder Inc., and others. The company believes its neurostimulation technology has the potential to deliver more targeted direct cortical stimulation that could provide superior results.

Comparison to Industry Standards

• The Argus II system was initially priced at approximately USD $115,000 in Europe and later reimbursed at approximately $150,000 for Medicare patients in the U.S.
• MicroTransponder Inc. sells the Vivistim FDA-approved vagus nerve stimulator (VNS) for stroke rehabilitation.
• Northstar Neuroscience, Inc. conducted clinical studies using a single-channel electrical stimulation device for stroke recovery but failed to achieve statistical significance in its Phase 3 study.
• Pixium Vision SA was developing the PRIMA (sub-retinal implant) in Dry-AMD patients but has entered judicial liquidation proceedings, with Science Corp. acquiring certain assets.
• Neuralink company has demonstrated a penetrating electrode cortical implant in animal models and has announced implanting its first patient with their brain computer interface (BCI) device.

Legal Proceedings

• The company is currently involved in a single pending opposition in the European Patent Office (EPO) challenging the validity of European patent no. EP2185236 titled Implantable Device for the Brain owned by Cortigent.

Related Party Transactions

• Vivani Medical, Inc. is the parent company of Cortigent and has provided funding and support services to Cortigent.
• Cortigent and Vivani have entered into a Transition Funding, Support and Services agreement, which includes provisions for repayment of amounts owed to Vivani from the IPO proceeds.
• Vivani will provide the services of its Chief Operating Officer and Chief Business Officer to Cortigent on an interim basis.
• Vivani has guaranteed the lease agreement for Cortigent's headquarters.
• Vivani will beneficially own approximately 77% of Cortigent's voting power post-IPO, making Cortigent a controlled company.

Stakeholder Impact

• Shareholders: Potential for value appreciation if Cortigent successfully develops and commercializes its products, but also risk of dilution and losses.
• Employees: Opportunity to work on innovative technologies, but also risk of job insecurity due to the company's financial situation.
• Patients: Potential to benefit from new treatments for blindness and stroke recovery, but also risk of adverse events and limited efficacy.
• Suppliers: Opportunity to provide materials and services to Cortigent, but also risk of payment delays or contract termination.
• Creditors: Risk of default if Cortigent is unable to generate sufficient revenue or raise additional capital.

Next Steps

• Cortigent plans to manufacture and validate new Orion devices for a planned pivotal clinical trial.
• The company intends to commence the pivotal trial for Orion by mid-2026 and complete it by mid-2028.
• Cortigent aims to begin an early feasibility study for the stroke recovery system in mid-2026 and a pivotal trial in late 2027.
• The company will work with the FDA to gain agreement on the additional clinical studies that will be required to secure marketing approval for Orion.

Key Dates

Keywords

neurostimulation, Orion, stroke recovery, artificial vision, clinical trials, FDA approval, medical devices, IPO, Cortigent, Vivani